日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Safety and effectiveness of post-trastuzumab deruxtecan regimens in patients with HER2-positive metastatic breast cancer who discontinued trastuzumab deruxtecan due to interstitial lung disease

因间质性肺病而停用曲妥珠单抗德鲁替康的HER2阳性转移性乳腺癌患者,在停用曲妥珠单抗德鲁替康后,后续治疗方案的安全性和有效性

Tsurutani, Junji; Nozawa, Kazuki; Mukohara, Toru; Taira, Tetsuhiko; Yoshimura, Akiyo; Nagai, Shigenori E; Hashimoto, Jun; Matsuura, Kazuo; Mizuno, Toshiro; Shinden, Yoshiaki; Yamamoto, Mitsugu; Takano, Toshimi; Wakahara, Makoto; Terakawa, Hirofumi; Yamanaka, Takashi; Kojima, Yasuyuki; Nakayama, Takahiro; Hirakawa, Yuji; Shiosakai, Kazuhito; Iwata, Hiroji

Real-world analysis of interstitial lung disease/pneumonitis in Japanese patients with breast cancer receiving trastuzumab deruxtecan

真实世界分析接受曲妥珠单抗德鲁替康治疗的日本乳腺癌患者间质性肺病/肺炎的发生情况

Tsurutani, Junji; Noguchi, Kengo; Tanabe, Ayumi

Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial

曲妥珠单抗德鲁替康治疗HER2低表达转移性乳腺癌:随机3期DESTINY-Breast04试验的长期生存分析

Modi, Shanu; Jacot, William; Iwata, Hiroji; Park, Yeon Hee; Vidal Losada, Maria; Li, Wei; Tsurutani, Junji; Ueno, Naoto T; Zaman, Khalil; Prat, Aleix; Papazisis, Konstantinos; Rugo, Hope S; Yamashita, Toshinari; Harbeck, Nadia; Im, Seock-Ah; De Laurentiis, Michelino; Pierga, Jean-Yves; Wang, Xiaojia; Gombos, Andrea; Tokunaga, Eriko; Orbegoso Aguilar, Cecilia; Yung, Lotus; Xiao, Feng; Cheng, Yingkai; Cameron, David

Trastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for Human Epidermal Growth Factor 2-Positive Locally Advanced/Metastatic Breast Cancer: The Randomized Noninferiority Phase III EMERALD Trial

曲妥珠单抗-帕妥珠单抗联合艾立布林或紫杉烷类药物作为人表皮生长因子2阳性局部晚期/转移性乳腺癌的一线化疗方案:随机非劣效性III期EMERALD试验

Yamashita, Toshinari; Saji, Shigehira; Takano, Toshimi; Naito, Yoichi; Tsuneizumi, Michiko; Yoshimura, Akiyo; Takahashi, Masato; Tsurutani, Junji; Iwatani, Tsuguo; Kitada, Masahiro; Tada, Hiroshi; Mori, Natsuko; Higuchi, Toru; Iwasa, Tsutomu; Araki, Kazuhiro; Koizumi, Kei; Hasegawa, Hiroki; Uchida, Yohei; Morita, Satoshi; Masuda, Norikazu

Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01

达托泊单抗德鲁替康对比化疗治疗既往接受过治疗的不可手术/转移性激素受体阳性、人表皮生长因子受体2阴性乳腺癌:TROPION-Breast01研究的主要结果

Bardia, Aditya; Jhaveri, Komal; Im, Seock-Ah; Pernas, Sonia; De Laurentiis, Michelino; Wang, Shusen; Martínez Jañez, Noelia; Borges, Giuliano; Cescon, David W; Hattori, Masaya; Lu, Yen-Shen; Hamilton, Erika; Zhang, Qingyuan; Tsurutani, Junji; Kalinsky, Kevin; Rubini Liedke, Pedro Emanuel; Xu, Lu; Fairhurst, Rick M; Khan, Sabrina; Denduluri, Neelima; Rugo, Hope S; Xu, Binghe; Pistilli, Barbara

Patient-reported outcomes with trastuzumab deruxtecan in hormone receptor-positive, HER2-low or HER2-ultralow metastatic breast cancer: results from the randomized DESTINY-Breast06 trial

曲妥珠单抗德鲁替康治疗激素受体阳性、HER2低表达或HER2超低表达转移性乳腺癌的患者报告结局:来自随机DESTINY-Breast06试验的结果

Hu, X; Curigliano, G; Yonemori, K; Bardia, A; Barrios, C H; Sohn, J; Lévy, C; Jacot, W; Tsurutani, J; Roborel de Climens, A; Wu, X; Andrzejuk-Ćwik, A; Mbanya, Z; Dent, R

Analytical and clinical validation of PATHWAY HER2 (4B5) assay for assessment of HER2-low/HER2-ultralow status and eligibility for trastuzumab deruxtecan in DESTINY-Breast06

在DESTINY-Breast06研究中,对PATHWAY HER2 (4B5)检测方法进行分析和临床验证,以评估HER2低表达/HER2超低表达状态以及患者是否适合接受曲妥珠单抗德鲁替康治疗。

Shami, R; Salgado, R; Bardia, A; Curigliano, G; Hu, X; Dent, R; Pierga, J-Y; Tsurutani, J; Wildiers, H; Ricciardi, G; Marchiò, C; Penault-Llorca, F; Bor-Angelier, C; Manoogian, M; Lucas, S; Olson, M T; Liu, X; Toro, P; Baker, A F; Fang, Q; Su, J; Yoder, A; Andrzejuk-Ćwik, A; Darilay, A; Matsuo, T; Jones, F; Viale, G

Effectiveness of post-trastuzumab deruxtecan treatments and incidence of interstitial lung disease in HER2-positive metastatic breast cancer: a real-world, observational cohort study

曲妥珠单抗联合德鲁替康治疗后HER2阳性转移性乳腺癌患者间质性肺病发生率的疗效:一项真实世界观察性队列研究

Nozawa, K; Iwata, H; Mukohara, T; Taira, T; Yoshimura, A; Nagai, S E; Hashimoto, J; Matsuura, K; Mizuno, T; Shinden, Y; Yamamoto, M; Takano, T; Wakahara, M; Terakawa, H; Yamanaka, T; Kojima, Y; Nakayama, T; Hirakawa, Y; Kuge, K; Tanabe, A; Tsurutani, J

From progress to plateau: 50-year trends in hypertension and salt intake in Finland

从进步到停滞:芬兰高血压和盐摄入量的50年趋势

Balasubbramanian, Dakshnapriya; Lopez Gelston, Catalina A; Rutkowski, Joseph M; Mitchell, Brett M; Inoue, Kosuke; Omura, Masao; Hirfumi, Horikoshi; Tsurutani, Yuya; Saito, Jun; Nishikawa, Tetsuo; Santalahti, A; Ojanen, A; Palosaari, T; Jääskeläinen, T; Kaartinen, N; Sääksjärvi, K; Laatikainen, T; Lundqvist, A

Recent Advances in the Development and Clinical Use of HER2 Inhibitors in Non-Small Cell Lung Cancer

非小细胞肺癌中HER2抑制剂的研发和临床应用最新进展

Ekyalongo, Richy; Yamaoka, Toshimitsu; Tsurutani, Junji